Literature DB >> 10573493

Coronary revascularisation for postischaemic heart failure: how myocardial viability affects survival.

D Pagano1, M E Lewis, J N Townend, P Davies, P G Camici, R S Bonser.   

Abstract

OBJECTIVE: To assess the impact of revascularisation of viable myocardium on survival in patients with postischaemic heart failure.
METHODS: 35 patients (mean (SD) age 58 (7) years) with severe heart failure (New York Heart Association (NYHA) functional class > or = III), mean left ventricular ejection fraction (LVEF) 24 (7)% (range 10-35%), and limited exercise capacity (peak oxygen consumption (VO(2)) 15 (4) ml/kg/min) were studied. 21/35 patients had no angina. Myocardial viability was assessed with quantitative positron emission tomography and the glucose analogue (18)F-fluorodeoxyglucose (FDG) (viable segment = FDG uptake > or = 0.25 micromol/min/g) in all patients before coronary artery bypass grafting. Patients were divided into two groups: group 1, > or = 8 viable dysfunctional segments (mean 12 (2), range 8-15); and group 2, < 8 viable dysfunctional segments (mean 3.5 (3), range 0-7). The two groups were comparable for age, sex, NYHA class, LVEF, and peak VO(2).
RESULTS: Two patients died perioperatively and seven patients died during follow up (mean 33 (14) months). All deaths were from cardiac causes. Kaplan-Meyer survival analysis showed 86% survival for group 1 patients versus 57% for group 2 (p = 0.03). Analysis by Cox proportional hazard model revealed three independent factors for cardiac event free survival: presence of > or = 8 viable segments (p = 0.006); preoperative LVEF (p = 0.002); and patient age (p = 0.01).
CONCLUSION: Revascularisation for postischaemic heart failure can be associated with good survival, which is critically dependent upon the amount of viable myocardium.

Entities:  

Mesh:

Year:  1999        PMID: 10573493      PMCID: PMC1729216          DOI: 10.1136/hrt.82.6.684

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

1.  An overview of contemporary etiologies of congestive heart failure.

Authors:  J R Teerlink; S Z Goldhaber; M A Pfeffer
Journal:  Am Heart J       Date:  1991-06       Impact factor: 4.749

2.  The hibernating myocardium.

Authors:  S H Rahimtoola
Journal:  Am Heart J       Date:  1989-01       Impact factor: 4.749

3.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

4.  Anaerobic threshold and respiratory gas exchange during exercise.

Authors:  K Wasserman; B J Whipp; S N Koyl; W L Beaver
Journal:  J Appl Physiol       Date:  1973-08       Impact factor: 3.531

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  The impact of 'Shahal' (a new cardiac emergency service) on subscribers' requests for medical assistance: characteristics and distribution of calls.

Authors:  A Roth; M Herling; V Vishlitzki
Journal:  Eur Heart J       Date:  1995-01       Impact factor: 29.983

7.  Angiotensin converting enzyme inhibitors in heart failure: how good are they?

Authors:  J N Townend; W A Littler
Journal:  Br Heart J       Date:  1993-05

8.  Dobutamine stress echocardiography: correlation with coronary lesion severity as determined by quantitative angiography.

Authors:  D S Segar; S E Brown; S G Sawada; T Ryan; H Feigenbaum
Journal:  J Am Coll Cardiol       Date:  1992-05       Impact factor: 24.094

9.  Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.

Authors:  H J Bonnier; R F Visser; H C Klomps; H J Hoffmann
Journal:  Am J Cardiol       Date:  1988-07-01       Impact factor: 2.778

10.  Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction.

Authors:  I Afridi; P A Grayburn; J A Panza; J K Oh; W A Zoghbi; T H Marwick
Journal:  J Am Coll Cardiol       Date:  1998-10       Impact factor: 24.094

View more
  9 in total

Review 1.  Radionuclide techniques for the assessment of myocardial viability and hibernation.

Authors:  J J Bax; E E van der Wall; M Harbinson
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

Review 2.  Metabolic imaging using PET.

Authors:  Takashi Kudo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-05       Impact factor: 9.236

Review 3.  Hibernation and congestive heart failure.

Authors:  David P Dutka; Paolo G Camici
Journal:  Heart Fail Rev       Date:  2003-04       Impact factor: 4.214

Review 4.  Coronary artery surgery for ischaemic heart failure: the surgeon's view.

Authors:  Michael Edward Lewis; Michael Paul Ian Pitt; Robert Stuart Bonser; Domenico Pagano
Journal:  Heart Fail Rev       Date:  2003-04       Impact factor: 4.214

5.  Coronary recanalisation, myocardial viability, and ventricular remodelling after infarction.

Authors:  P G Camici
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

Review 6.  Diagnostic and clinical perspectives of fusion imaging in cardiology: is the total greater than the sum of its parts?

Authors:  J J Bax; R S Beanlands; F J Klocke; J Knuuti; A A Lammertsma; M A Schaefers; H R Schelbert; G K Von Schulthess; L J Shaw; G Z Yang; P G Camici
Journal:  Heart       Date:  2005-12-30       Impact factor: 5.994

7.  Radionuclide Imaging of Viable Myocardium: Is it Underutilized?

Authors:  Ilias Mylonas; Rob S B Beanlands
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-02-19

8.  Dark-blood late gadolinium enhancement without additional magnetization preparation.

Authors:  Robert J Holtackers; Amedeo Chiribiri; Torben Schneider; David M Higgins; René M Botnar
Journal:  J Cardiovasc Magn Reson       Date:  2017-08-23       Impact factor: 5.364

9.  Clinical value of dark-blood late gadolinium enhancement cardiovascular magnetic resonance without additional magnetization preparation.

Authors:  Robert J Holtackers; Caroline M Van De Heyning; Muhummad Sohaib Nazir; Imran Rashid; Ioannis Ntalas; Haseeb Rahman; René M Botnar; Amedeo Chiribiri
Journal:  J Cardiovasc Magn Reson       Date:  2019-07-29       Impact factor: 5.364

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.